180,865 results match your criteria Prostate


Circadian genes and risk of prostate cancer: findings from the EPICAP study.

Int J Cancer 2019 Jan 21. Epub 2019 Jan 21.

Université Paris-Saclay, Université Paris-Sud, CESP (Center for Research in Epidemiology and Population Health), Inserm, Team Cancer and Environment, Villejuif, France.

Circadian rhythms regulate several physiological functions and genes controlling the circadian rhythm were found to regulate cell proliferation, cell cycle and apoptosis. Few studies have investigated the role of those circadian genes in prostate cancer occurrence. We aim to investigate the relationship between circadian genes polymorphisms and prostate cancer risk based on data from the EPICAP study, a population-based case-control study including 1515 men (732 cases / 783 controls) with genotyped data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32149DOI Listing
January 2019

Vitamin D and Testosterone Co-ordinately Modulate Intracellular Zinc Levels and Energy Metabolism in Prostate Cancer Cells.

J Steroid Biochem Mol Biol 2019 Jan 18. Epub 2019 Jan 18.

Department of Biomedical Sciences, Cancer Research Center, School of Public Health, University at Albany, Rensselaer, NY, 12144, United States. Electronic address:

Vitamin D and its receptor are responsible for controlling energy expenditure in adipocytes and have direct roles in the transcriptional regulation of energy metabolic pathways. This phenomenon also has a significant impact on the etiology of prostate cancer (PCa). Using several in vitro models, the roles of vitamin D on energy metabolism and its implication in primary, early and late invasive PCa was investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jsbmb.2019.01.006DOI Listing
January 2019

Time to PSA Nadir and the Risk of Death from Prostate Cancer following Radiation and Androgen Deprivation Therapy.

Urology 2019 Jan 18. Epub 2019 Jan 18.

Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA.

Objective: To assess whether the time to PSA nadir (TTN) has differential prognostic value in men who reach an undetectable versus detectable PSA nadir.

Methods: Two-hundred and four men from a prospective randomized controlled trial (RCT) involving radiation therapy with or without 6 months of androgen deprivation therapy (ADT) in unfavorable risk CaP at academic or community based centers in Massachusetts, enrolled between 1995 and 2001. Adjusted hazard ratios (AHR) of the risk of CaP-specific mortality (PCSM) calculated using Fine and Gray competing risk regression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2018.11.056DOI Listing
January 2019

A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.

Prostate Cancer Prostatic Dis 2019 Jan 21. Epub 2019 Jan 21.

Department of Medicine, Nephrology Division, Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC, USA.

Purpose: The objective of this study was to test a low-carbohydrate diet (LCD) plus walking to reduce androgen deprivation therapy (ADT)-induced metabolic disturbances.

Materials And Methods: This randomized multi-center trial of prostate cancer (PCa) patients initiating ADT was designed to compare an LCD (≤20g carbohydrate/day) plus walking (≥30 min for ≥5 days/week) intervention vs. control advised to maintain usual diet and exercise patterns. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-019-0126-5DOI Listing
January 2019

Exploring the risk-reward balance in focal therapy for prostate cancer-a contribution to the debate.

Prostate Cancer Prostatic Dis 2019 Jan 21. Epub 2019 Jan 21.

Department of Health Evidence, Radboud Institute for Health Sciences, Radboudumc, Nijmegen, The Netherlands.

Focal therapy (FT) for the treatment of localized prostate cancer offers an alternative strategy for men seeking active treatment. Although relatively new, existing studies suggest that the majority of men who undergo FT tend to maintain levels of genito-urinary function that are indistinguishable from their pre-treatment status. However, as part of the shared decision making process, men need to balance good tolerability against a greater risk of recurrence given that much of the prostate remains intact after FT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-018-0125-yDOI Listing
January 2019

Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).

Prostate Cancer Prostatic Dis 2019 Jan 21. Epub 2019 Jan 21.

Cancer Prevention Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Background: For men on active surveillance for prostate cancer, biomarkers may improve prediction of reclassification to higher grade or volume cancer. This study examined the association of urinary PCA3 and TMPRSS2:ERG (T2:ERG) with biopsy-based reclassification.

Methods: Urine was collected at baseline, 6, 12, and 24 months in the multi-institutional Canary Prostate Active Surveillance Study (PASS), and PCA3 and T2:ERG levels were quantitated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-018-0124-zDOI Listing
January 2019

Prospective examination of the changes in the urinary microbiome induced by transrectal biopsy of the prostate using 16S rRNA gene analysis.

Prostate Cancer Prostatic Dis 2019 Jan 21. Epub 2019 Jan 21.

Department of Medical Microbiology, Immunology, and Cell Biology, Southern Illinois University School of Medicine, Springfield, IL, USA.

Objectives: To prospectively examine the changes in microbiota within the urinary tract after transrectal prostate biopsy.

Materials And Methods: Data, urine, and fecal samples prospectively collected from 30 patients before and after transrectal biopsy of the prostate. DNA was extracted from urine collected after a prostate massage before and after prostate biopsy, and from fecal samples collected before the biopsy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-018-0120-3DOI Listing
January 2019

Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis.

Oncogene 2019 Jan 21. Epub 2019 Jan 21.

Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands.

One of the mechanisms by which advanced prostate cancer develops resistance to androgen deprivation therapy is the elevated expression of C-terminally truncated androgen receptor (AR) variants. These variants, such as AR-V7, originate from aberrant splicing of the AR pre-mRNA and the inclusion of a cryptic exon containing a premature stop codon in the mRNA. The resulting loss of the ligand-binding domain allows AR-V7 to act as a constitutively active transcription factor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-019-0696-7DOI Listing
January 2019

Lactate modulates CD4 T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axis.

Oncogene 2019 Jan 21. Epub 2019 Jan 21.

Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50134, Florence, Italy.

Leukocyte infiltration plays an active role in controlling tumor development. In the early stages of carcinogenesis, T cells counteract tumor growth. However, in advanced stages, cancer cells and infiltrating stromal components interfere with the immune control and instruct immune cells to support, rather than counteract, tumor malignancy, via cell-cell contact or soluble mediators. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-019-0688-7DOI Listing
January 2019

HepaCAM inhibits cell proliferation and invasion in prostate cancer by suppressing nuclear translocation of the androgen receptor via its cytoplasmic domain.

Mol Med Rep 2019 Jan 10. Epub 2019 Jan 10.

Department of Urology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, P.R. China.

Hepatocyte cell adhesion molecule (HepaCAM) is a tumour suppressor. However, the mechanism of HepaCAM function in prostate cancer (PCa) remains unknown. In the present study, HepaCAM, androgen receptor (AR) and Ran were analysed in 46 PCa tissue samples using immunohistochemistry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mmr.2019.9841DOI Listing
January 2019

Active Surveillance of Prostate Cancer is a Viable Option in Men Younger Than 60 Years.

J Urol 2019 Jan 16. Epub 2019 Jan 16.

Department of Urology, Harvard Medical School, Boston, Massachusetts.

Purpose: At most centers strict age criteria lacking for eligibility for active surveillance of prostate cancer. Younger men are often counseled to undergo definitive treatment despite limited data on the outcomes of active surveillance in younger men. We compared clinical characteristics and outcomes in men who enrolled in active surveillance at age less than 60 vs 60 years old or older. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000031DOI Listing
January 2019

Mesenchymal Stem Cell Isolation from Pulp Tissue and Co-Culture with Cancer Cells to Study Their Interactions.

J Vis Exp 2019 Jan 7(143). Epub 2019 Jan 7.

Genetics and Bioengineering, Yeditepe University.

Cancer as a multistep process and complicated disease is not only regulated by individual cell proliferation and growth but also controlled by tumor environment and cell-cell interactions. Identification of cancer and stem cell interactions, including changes in extracellular environment, physical interactions, and secreted factors, might enable the discovery of new therapy options. We combine known co-culture techniques to create a model system for mesenchymal stem cells (MSCs) and cancer cell interactions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3791/58825DOI Listing
January 2019

Riboflavin immobilized FeO magnetic nanoparticles carried with n-butylidenephthalide as targeting-based anticancer agents.

Artif Cells Nanomed Biotechnol 2019 Dec;47(1):210-220

a Department of Applied Chemistry , National Chiao Tung University , Hsinchu , Taiwan.

n-Butylidenephthalide (BP) is a potential anti-cancer drug, which can be extracted from Angelica sinensis (Danggui). Previous reports have shown the effectiveness of BP in treating cancer diseases. However, BP has no targeting capacity towards specific cancer cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21691401.2018.1548473DOI Listing
December 2019

Citriperazines A-D produced by a marine algae-derived fungus Penicillium sp. KMM 4672.

Nat Prod Res 2019 Jan 19:1-6. Epub 2019 Jan 19.

a G.B. Elyakov Pacific Institute of Bioorganic Chemistry , Vladivostok , Russia.

Four new diketopiperazine alkaloids, citriperazines A-D were isolated from algae-derived Penicillium sp. KMM 4672. The structures of compounds 1-4 were determined using spectroscopic methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14786419.2018.1552696DOI Listing
January 2019

Vasa nervorum angiogenesis in prostate cancer with perineural invasion.

Prostate 2019 Jan 20. Epub 2019 Jan 20.

Icahn School of Medicine at Mount Sinai, Department of Cell, Developmental and Regenerative Biology, New York, New York.

Background: Perineural invasion (PNI) is generally accepted as a major route of cancer dissemination in malignancies associated with highly enervated organs. However, the effect of cancer cells on vasa nervorum remains unknown. We studied this effect in locally advanced prostate cancer, a high-risk feature associated with approximately 20% of prostate cancer specific mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23771DOI Listing
January 2019

Alternol eliminates excessive ATP production by disturbing Krebs cycle in prostate cancer.

Prostate 2019 Jan 20. Epub 2019 Jan 20.

Department of Urology, The University of Kansas Medical Center, Kansas City, Kansas.

Background: Alternol is a natural compound isolated from fermentation products of a mutant fungus. Our previous studies demonstrated that Alternol specifically kills cancer cells but spares benign cells.

Methods: To investigate the mechanism underlying alternol-induced cancer cell-specific killing effect, we took a comprehensive strategy to identify Alternol's protein targets in prostate cancer cells, including PC-3, C4-2, and 22RV1, plus benign BPH1 cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23767DOI Listing
January 2019

Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.

Prostate 2019 Jan 20. Epub 2019 Jan 20.

Progenics Pharmaceuticals, Inc., New York, New York.

Background: Prostate-specific membrane antigen (PSMA) is a well-characterized target that is overexpressed selectively on prostate cancer cells. PSMA antibody-drug conjugate (ADC) is a fully human IgG1 monoclonal antibody conjugated to the microtubule disrupting agent monomethyl auristatin E (MMAE), which is designed to specifically bind PSMA-positive cells, internalize, and then release its cytotoxic payload into the cells. PSMA ADC has demonstrated potent and selective antitumor activity in preclinical models of advanced prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23765DOI Listing
January 2019

Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.

J Immunol Res 2018 19;2018:4325874. Epub 2018 Dec 19.

Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, Taiwan.

Recently, increasing data show that immunotherapy could be a powerful weapon against cancers. Comparing to the traditional surgery, chemotherapy or radiotherapy, immunotherapy more specifically targets cancer cells, giving rise to the opportunities to the patients to have higher response rates and better quality of life and even to cure the disease. Cancer vaccines could be designed to target tumor-associated antigens (TAAs), cancer germline antigens, virus-associated antigens, or tumor-specific antigens (TSAs), which are also called neoantigens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/4325874DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313977PMC
December 2018

Intelligent Photosensitive Mesenchymal Stem Cells and Cell-Derived Microvesicles for Photothermal Therapy of Prostate Cancer.

Nanotheranostics 2019 11;3(1):41-53. Epub 2018 Nov 11.

Shanghai East Hospital; The Institute for Biomedical Engineering & Nano Science, Tongji University School of Medicine, Shanghai, 200120, China.

Targeted delivery of nanomedicines into the tumor site and improving the intratumoral distribution remain challenging in cancer treatment. Here, we report an effective transportation system utilizing both of mesenchymal stem cells (MSCs) and their secreted microvesicles containing assembled gold nanostars (GNS) for targeted photothermal therapy of prostate cancer. The stem cells act as a cell carrier to actively load and assemble GNS into the lysosomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/ntno.28450DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328305PMC
November 2018

miR-338-3p targets and suppresses tumorigenicity of prostate cancer cells.

Am J Cancer Res 2018 1;8(12):2564-2574. Epub 2018 Dec 1.

Department of Radiation Oncology, First Affiliated Hospital, Guangzhou Medical University Guangzhou 510120, Guangdong, China.

MicroRNA-338-3p (miR-338-3p) has been implicated in several cancers; however, its role in human prostate cancer remains unknown. In this study, we observed downregulation of miR-338-3p in prostate cancer tissues and cell lines. Forced expression of miR-338-3p suppressed prostate cancer cell proliferation, migration, and invasion and tumor growth , while apoptosis was induced. Read More

View Article

Download full-text PDF

Source
December 2018

Anemia is associated with poor outcomes of metastatic castration-resistant prostate cancer, a systematic review and meta-analysis.

Am J Transl Res 2018 15;10(12):3877-3886. Epub 2018 Dec 15.

Department of Medical Oncology, Sir Run Run Shaw Hospital, Medical School of Zhejiang University Hangzhou, China.

Androgen deprivation therapy (ADT) was an important management for metastatic prostate cancer. However, patients would finally progress to the metastatic castration-resistant prostate cancer (mCRPC) and lose sensitivity to ADT. In addition to lower testosterone level, ADT could cause anemia, which might impair the chemotherapy efficiency and worsen the outcomes of cancer patients. Read More

View Article

Download full-text PDF

Source
December 2018

Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis.

J Cancer 2019 1;10(1):120-130. Epub 2019 Jan 1.

Department of Thoracic Surgery, Jiangxi Cancer Hospital, People's Republic of China.

Little is known about the incidence of ipilimumab-related serious adverse events (SAEs) across various tumor types, drug doses and treatment regimens. PubMed database was searched up to November, 2017 to identify prospective clinical trials of ipilimumab therapy for adult patients with cancer. Comparisons of the incidence were based on the χ test in univariate analysis and the logistic regression model in multivariate analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.28120DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329845PMC
January 2019

The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score is a Novel Significant Prognostic Factor for Patients with Metastatic Prostate Cancer Undergoing Cytoreductive Radical Prostatectomy.

J Cancer 2019 1;10(1):81-91. Epub 2019 Jan 1.

Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P.R. China.

: The hemoglobin, albumin, lymphocyte, and platelet (HALP) score has been shown to be an important prognostic marker in some tumor types. The aim of this study was to evaluate the prognostic impact of the preoperative HALP score, with the intent to develop a new prognostic index for patients with metastatic prostate cancer (mPCA) after cytoreductive radical prostatectomy (cRP). We retrospectively analyzed the data from 82 patients with mPCA after cRP in our institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.27210DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329846PMC
January 2019

SpaceOAR to improve dosimetric outcomes for monotherapy high-dose-rate prostate implantation in a patient with ulcerative colitis.

J Contemp Brachytherapy 2018 Dec 28;10(6):577-582. Epub 2018 Dec 28.

Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.

High-dose-rate (HDR) brachytherapy is an attractive option for patients receiving definitive radiation therapy for prostate cancer with decreased overall dose to the pelvis. However, ulcerative colitis increases rectal toxicity risk and may be a contraindication. A synthetic hydrogel, SpaceOAR (Augmentix Inc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/jcb.2018.81001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335554PMC
December 2018

Importance of dynamic contrast enhanced magnetic resonance imaging for targeting biopsy and salvage treatments after prostate cancer recurrence.

J Contemp Brachytherapy 2018 Dec 28;10(6):570-572. Epub 2018 Dec 28.

Department of Medical Physics, Leeds Cancer Centre, St. James's University Hospital, Leeds.

Purpose: Evaluate T2 weighted MRI (T2W), diffusion weighted imaging (DWI), and dynamic contrast enhanced MRI (DCE-MRI) for determining areas of prostate cancer recurrence to target biopsy or salvage treatment in patients previously treated with I-125 seed brachytherapy.

Material And Methods: MRI data from 15 patients, whose primary treatment was I-125 seed brachytherapy and who were subsequently treated with partial gland salvage high-dose-rate brachytherapy were retrospectively analyzed. Two radiologists independently reviewed imaging on two occasions blinded to clinical and biopsy information. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/jcb.2018.79667DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335551PMC
December 2018

Brachytherapy for localized prostate cancer in the modern era: a comparison of patient-reported quality of life outcomes among different techniques.

J Contemp Brachytherapy 2018 Dec 28;10(6):495-502. Epub 2018 Dec 28.

Department of Radiation Oncology.

Purpose: To report our institutional quality of life (QOL) data for low-dose-rate (LDR) monotherapy (LDR mono), high-dose-rate (HDR) monotherapy (HDR mono), and EBRT with an HDR brachytherapy boost (HDR boost).

Material And Methods: The charts of 165 patients with localized adenocarcinoma of the prostate treated with LDR monotherapy (LDR mono), HDR monotherapy (HDR mono), and EBRT with an HDR brachytherapy boost (HDR boost) at a single institution between 2012 and 2015 were reviewed. All patients completed the American Urological Association symptom score (AUASS) and Expanded Prostate Index for Prostate Cancer - Clinical Practice (EPIC-CP) quality of life assessments prior to treatment and at least one follow-up survey. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/jcb.2018.81024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335553PMC
December 2018

The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma.

J Oncol 2018 18;2018:1953571. Epub 2018 Dec 18.

Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Republic of Korea.

Purpose: This study aimed to determine whether baseline blood inflammatory markers can predict progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).

Methods: The study included 158 patients with mRCC treated with first-line targeted therapy between 2002 and 2016. A multivariable cox proportional hazards model identified inflammatory factors that predict PFS and OS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/1953571DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312581PMC
December 2018

The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins.

Front Pharmacol 2018 4;9:1515. Epub 2019 Jan 4.

Department of Clinical Nutrition, University of Texas Southwestern Medical Center, Dallas, TX, United States.

The mevalonate pathway provides sterols for membrane structure and nonsterol intermediates for the post-translational modification and membrane anchorage of growth-related proteins, including the Ras, Rac, and Rho GTPase family. Mevalonate-derived products are also essential for the Hedgehog pathway, steroid hormone signaling, and the nuclear localization of Yes-associated protein and transcriptional co-activator with PDZ-binding motif, all of which playing roles in tumorigenesis and cancer stem cell function. The phosphatidylinositol-4,5-bisphosphate 3-kinase-AKT-mammalian target of rapamycin complex 1 pathway, p53 with gain-of-function mutation, and oncoprotein MYC upregulate the mevalonate pathway, whereas adenosine monophosphate-activated protein kinase and tumor suppressor protein RB are the downregulators. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2018.01515DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328495PMC
January 2019

Establishing a prediction model for prostate cancer bone metastasis.

Int J Biol Sci 2019 1;15(1):208-220. Epub 2019 Jan 1.

Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.

We collected clinical data from 308 prostate cancer (PCa) patients to investigate the clinical characteristics and independent risk factors of bone metastasis (BM) and to establish a prediction model for BM of PCa and determine the necessity of bone scans. Univariate and multivariate analyses were performed based on age, biopsy Gleason score (BGS), clinical tumor stage (cTx), total prostate specific antigen (tPSA), free prostate specific antigen (fPSA), fPSA/tPSA, prostate volume, alkaline phosphatase (ALP), serum calcium and serum phosphorus. Moreover, 80 of the 308 PCa patients had a PI-RADS v2 score and were analysed retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/ijbs.27537DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329914PMC
January 2019

Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculature.

Int J Med Sci 2019 1;16(1):115-124. Epub 2019 Jan 1.

Department of Urology, Medical University Innsbruck, Austria.

The magic roundabout receptor 4 (Robo 4) is a tumor endothelial marker expressed in the vascular network of various tumor entities. However, the role of Robo 4 in prostate cancer (PCa), the second common cause of cancer death among men in -developed countries, has not been described yet. Thus, the present study investigates for the first time the impact of Robo 4 in PCa both in the clinical setting and . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/ijms.28735DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332478PMC
January 2019

Differentiation among prostate cancer patients with Gleason score of 7 using histopathology whole-slide image and genomic data.

Proc SPIE Int Soc Opt Eng 2018 Feb 6;10579. Epub 2018 Mar 6.

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Prostate cancer is the most common non-skin related cancer affecting 1 in 7 men in the United States. Treatment of patients with prostate cancer still remains a difficult decision-making process that requires physicians to balance clinical benefits, life expectancy, comorbidities, and treatment-related side effects. Gleason score (a sum of the primary and secondary Gleason patterns) solely based on morphological prostate glandular architecture has shown as one of the best predictors of prostate cancer outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1117/12.2293193DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338219PMC
February 2018

Performance of urinary survivin as a non-invasive molecular marker of bladdercarcinoma in a schistosomiasis endemic area.

Ghana Med J 2018 Jun;52(2):74-78

Urology Division, Department of Surgery, Ahmadu Bello University Teaching Hospital Zaria, Nigeria.

Objective: To compare the sensitivity, specificity, positive predictive value, negative predictive value of urinary survivin and that of urine cytology in the diagnosis of bladder carcinoma in a schistosoma endemic area.

Design And Setting: This is a 12-month prospective study of patients with features of bladder carcinoma as study group and patients with other urologic conditions and healthy volunteers as control group.

Participants: Patients with features of bladder carcinoma formed the study group, while patients with other urological conditions and healthy volunteers formed the control group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4314/gmj.v52i2.2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326538PMC

An unusual metastasis of prostate cancer detected with Ga-PSMA PET/CT imaging: Corpus spongiosum of the radix penis.

Rev Esp Med Nucl Imagen Mol 2019 Jan 17. Epub 2019 Jan 17.

Gulhane Research and Training Hospital, Department of Urology, Ankara, Turquía.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.remn.2018.09.008DOI Listing
January 2019

[Urinary incontinence after HOLEP: Incidence, evolution and predictive factors].

Prog Urol 2019 Jan 17. Epub 2019 Jan 17.

Hopital Cochin, 75014 Paris, France. Electronic address:

Objective: Assess the early morbidity after HOLEP, the urinary incontinence in particular, and specify its different types, evolution, and predictive factors.

Patients And Methods: We conducted an observational, analytical, retrospective, monocentric study including all patients undergoing surgery for benign prostatic hypertrophy (HBP) by HoLEP between November 2015 and January 2017. The data were collected pre-, per- and postoperatively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.purol.2018.12.008DOI Listing
January 2019

RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment.

Crit Rev Oncol Hematol 2019 Jan 3;133:85-91. Epub 2018 Nov 3.

Department of Histopathology, Antwerp University Hospital, Edegem, B2650, Belgium.

Binding between the receptor activator of nuclear factor-kB (RANK) and its ligand (RANKL) triggers recruitment of TNF receptor associated factor (TRAF) adaptor proteins and activation of downstream pathways. RANK/RANKL signaling is controlled by a decoy receptor called osteoprotegerin (OPG) which interacts with RANKL. Additional networks regulating RANK/RANKL signaling are active in a context specific manner. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2018.10.011DOI Listing
January 2019

Co-crystallization for enhanced dissolution rate of bicalutamide: Preparation and evaluation of rapidly disintegrating tablets.

Drug Dev Ind Pharm 2019 Jan 19:1-32. Epub 2019 Jan 19.

a College of Pharmacy, Tanta University , Tanta , Egypt.

Objectives: Enhance the dissolution rate of bicalutamide via co-crystallization with sucralose (sweetener), with the aim to develop rapidly disintegrating tablets with subsequent prompt dissolution.

Significance: Bicalutamide is antiandrogenic agent for treatment of prostate cancer but has low and variable oral bioavailability, mainly attributed to poor dissolution. Co-crystallization with benign excipients is promising for dissolution enhancement with the additive serving dual functions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03639045.2019.1571504DOI Listing
January 2019

The impact of cancer type, treatment, and distress on health-related quality of life: cross-sectional findings from a study of Australian cancer patients.

Support Care Cancer 2019 Jan 19. Epub 2019 Jan 19.

School of Psychology, Deakin University, Melbourne, Victoria, 3125, Australia.

Purpose: This study examined the mediating effects of cancer type, treatment, and distress on health-related quality of life (HRQoL) for early diagnosis cancer patients. Results were interpreted with respect to established thresholds for clinical meaningfulness.

Methods: A cross-sectional design was used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-018-4625-zDOI Listing
January 2019

Urothelial carcinoma with villoglandular differentiation (UCVGD) with small cell neuroendocrine carcinoma of urinary bladder.

BMJ Case Rep 2019 Jan 18;12(1). Epub 2019 Jan 18.

Urology, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, Orissa, India.

Urothelial carcinoma with villoglandular differentiation (UCVGD) is a rare aggressive variant of urothelial carcinoma. It is usually associated with high-grade urothelial carcinoma or rarely adenocarcinoma. There is only one other previous report of UCVGD associated with small cell neuroendocrine carcinoma of urinary bladder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-228017DOI Listing
January 2019

Personality and preventive healthcare utilisation: Evidence from the IRISH Longitudinal Study on Ageing.

Prev Med 2019 Jan 17. Epub 2019 Jan 17.

Health Economics, University of Birmingham, Birmingham, UK.

There is extensive empirical evidence that personality is associated with many outcomes and behaviours, such as educational outcomes, labour market participation, savings behaviour, health behaviours, physical health status and mortality. Use of preventive healthcare services (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ypmed.2018.12.029DOI Listing
January 2019

Estrogen receptors localization and signaling pathways in DU-145 human prostate cancer cells.

Mol Cell Endocrinol 2019 Jan 17. Epub 2019 Jan 17.

Laboratory of Experimental Endocrinology, Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Pedro de Toledo 669, Vila Clementino, São Paulo, SP, 04039-032, Brazil. Electronic address:

The aim of the present study was to investigate the subcellular localization of estrogen receptors ERα and ERβ in androgen-independent prostate cancer cell line DU-145, and the possible role of exportin CRM1 on ERs distribution. In addition, we evaluated the ERs contribution to activation of ERK1/2 and AKT. Immunostaining of ERα and ERβ was predominantly found in the extranuclear regions of DU-145 cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mce.2018.12.015DOI Listing
January 2019

Small Molecule BKM1972 Inhibits Human Prostate Cancer Growth and Overcomes Docetaxel Resistance in Intraosseous Models.

Cancer Lett 2019 Jan 17. Epub 2019 Jan 17.

Molecular Oncology and Biomarkers Program, Georgia Cancer Center, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, USA; Department of Urology and Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; MetCure Therapeutics LLC, Atlanta, GA, USA. Electronic address:

Bone metastasis is a major cause of prostate cancer (PCa) mortality. Although docetaxel chemotherapy initially extends patients' survival, in most cases PCa becomes chemoresistant and eventually progresses without a cure. In this study, we developed a novel small-molecule compound BKM1972, which exhibited potent in vitro cytotoxicity in PCa and other cancer cells regardless of their differences in chemo-responsiveness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2019.01.010DOI Listing
January 2019

The added value of systematic biopsy in men with suspicion of prostate cancer undergoing multiparametric MRI-targeted biopsy.

Urol Oncol 2019 Jan 16. Epub 2019 Jan 16.

Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; Department of Urology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands; Department of Electrical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.

Purpose: Incorporation of multiparametric magnetic resonance imaging (mpMRI) and targeted biopsy (TBx) in the diagnostic pathway for prostate cancer (CaP) is rapidly becoming common practice. In men with a prebiopsy positive mpMRI a TBx only approach, thereby omitting transrectal ultrasound-guided systematic biopsy (SBx), has been postulated. In this study we evaluated the additional clinical relevance of SBx in men with a positive prebiopsy mpMRI (Prostate Imaging Reporting and Data System [PI-RADS] ≥ 3) undergoing TBx for CaP detection, Gleason grading and CaP localization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2019.01.005DOI Listing
January 2019

Usefulness of 18F-fluorocoline PET/CT in prostate cancer patients with biochemical recurrence: Influence of PSA kinetics and hormone therapy.

Med Clin (Barc) 2019 Jan 16. Epub 2019 Jan 16.

UGC Medicina Nuclear, Hospital Universitario Virgen de las Nieves, Granada, España; IBS Granada, Instituto de Investigación Biosanitaria de Granada, Granada, España. Electronic address:

Purpose: To evaluate the capacity of 18f-fluorocholine positron emission tomography/computed tomography (FCH PET/CT) to detect biochemical recurrence of prostate cancer and to determine the correlation with PSA kinetics and influence of antiandrogen hormone therapy.

Patients And Methods: Observational and retrospective study, which included patients with prostate cancer and criteria for biochemical recurrence and/or resistance to castration, according to the European Association of Urology. FCH PET/CT results were classified as positive or negative, using as gold standard the pathology report, findings of other imaging test, and/or clinical follow-up results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.medcli.2018.11.018DOI Listing
January 2019

USE OF MRI-GUIDED BIOPSY FOR SELECTION AND FOLLOW-UP OF MEN UNDERGOING HEMI-GLAND CRYOABLATION OF PROSTATE CANCER.

Urology 2019 Jan 16. Epub 2019 Jan 16.

Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, 300 Stein Plaza, 3rd Floor, Los Angeles, CA 90095. Electronic address:

Objective: To investigate safety, efficacy, and quality of life impact of hemi-gland cryotherapy for clinically-significant prostate cancer, when patient selection and follow-up includes MRI-guided biopsy.

Methods: 29 men with unilateral prostate cancer (all clinically significant with prostate volume <60cc) were enrolled in a prospective observational trial of hemi-gland cryotherapy. Mean patient age was 68. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2018.11.052DOI Listing
January 2019

Aluminum disrupts the prenatal development of the male and female gerbil prostate (Meriones unguiculatus).

Exp Mol Pathol 2019 Jan 16. Epub 2019 Jan 16.

Department of Histology, Embryology and Cell Biology, Laboratory of Microscopy Applied to Reproduction, Institute of Biological Sciences, Federal University of Goiás, Goiânia, Goiás 74001970, Brazil. Electronic address:

Normal prostate development is highly dependent of an equilibrated hormonal regulation, so that sensible interferences during this period may predispose the gland to lesions during aging. Industrial activities have increased the exposure of this gland to active elements found in environment, such as aluminum (Al). Al presents toxic effect for living beings, having the potential to disrupt the development and growth of several organs and systems. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexmp.2019.01.005DOI Listing
January 2019

Epithelial DNA methyltransferase-1 regulates cell survival, growth and maturation in developing prostatic buds.

Dev Biol 2019 Jan 16. Epub 2019 Jan 16.

Department of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA. Electronic address:

DNA methyltransferase 1 (DNMT1) is required for embryogenesis but roles in late forming organ systems including the prostate, which emerges from the urethral epithelium, have not been fully examined. We used a targeted genetic approach involving a Shhcre recombinase to demonstrate requirement of epithelial DNA methyltransferase-1 (Dnmt1) in mouse prostate morphogenesis. Dnmt1 mutant urethral cells exhibit DNA hypomethylation, DNA damage, p53 accumulation and undergo cell cycle arrest and apoptosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ydbio.2019.01.011DOI Listing
January 2019

Effectiveness of the combination of vascular targeted photodynamic therapy and anti-cytotoxic T-lymphocyte-associated antigen 4 in a preclinical mouse model of urothelial carcinoma.

Int J Urol 2019 Jan 18. Epub 2019 Jan 18.

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.

Objective: To investigate the effectiveness of combination treatment of vascular targeted photodynamic therapy and anti-cytotoxic T-lymphocyte-associated antigen 4 immunotherapy in a mouse model of urothelial carcinoma.

Methods: We used C57BL/6 mice injected with murine bladder 49 cell line. Mice were randomly allocated into four treatment groups: vascular targeted photodynamic therapy only, anti-cytotoxic T-lymphocyte-associated antigen 4 only, combination therapy and control. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/iju.13878
Publisher Site
http://dx.doi.org/10.1111/iju.13878DOI Listing
January 2019
1 Read

Novel nomogram for the prediction of seminal vesicle invasion including multiparametric magnetic resonance imaging.

Int J Urol 2019 Jan 18. Epub 2019 Jan 18.

Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.

Objectives: To create a model that predicts side-specific seminal vesicle invasion using clinical, biopsy and multiparametric magnetic resonance imaging data.

Methods: We analyzed data from 544 patients who underwent robot-assisted radical prostatectomy at a single institution. To develop a side-specific predictive model, we ultimately considered four variables: prostate-specific antigen, highest ipsilateral biopsy Gleason grade, highest ipsilateral percentage core involvement and seminal vesicle invasion on multiparametric magnetic resonance imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iju.13905DOI Listing
January 2019

Editorial Comment from Dr Sadahira et al. to Use of fosfomycin as targeted antibiotic prophylaxis before prostate biopsy: A prospective randomized study.

Int J Urol 2019 Jan 18. Epub 2019 Jan 18.

Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iju.13907DOI Listing
January 2019

Exploration of Novel 5α-Reductase Inhibitors for Benign prostatic Hyperplasia by 2D/3D QSAR, Cytotoxicity Pre-ADME and Docking Studies.

Curr Top Med Chem 2019 Jan 19. Epub 2019 Jan 19.

University Institute of Pharmaceutical Sciences; Department of Pharmaceutical Chemistry Panjab University, Chandigarh -160014. India.

5α-Reductase (5AR) a NADPH dependent enzyme is expressed in most of the prostate epithelial cells. By converting testosterone (T) into more potent androgen dihydrotestosterone (DHT), it plays an important role in men physiology and represents an efficient therapeutic target for androgen dependent diseases. Over the last few years, significant efforts have been made in order to develop 5AR inhibitors (5ARI) to treat Benign Prostatic Hyperplasia because of excessive production of DHT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568026619666190119145959DOI Listing
January 2019